MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) Annual Meeting 2016
November 03, 2016 09:45 ET
|
Morphosys AG
Martinsried / Munich, Germany, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Oral presentations on proprietary antibody programs MOR208 and MOR202 MorphoSys AG (FSE: MOR; Prime Standard Segment;...
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology
November 02, 2016 02:34 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Nov. 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and LEO Pharma today announced that they have entered into a...
MorphoSys to Host Q3 2016 Conference Call on November 7, 2016
October 28, 2016 05:33 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Oct. 28, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2016 results on November 7, 2016 at 7:00 am...
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
October 20, 2016 01:34 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Oct. 20, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has received a milestone payment from...
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
October 17, 2016 01:35 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Oct. 17, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) presented updated safety and efficacy data from an ongoing phase...
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
October 01, 2016 06:51 ET
|
MorphoSys AG
Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- Guselkumab Met Co-Primary Endpoints in Patients with Moderate to Severe Plaque Psoriasis
Janssen today presented results from a...
Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis
October 01, 2016 06:48 ET
|
MorphoSys AG
Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research &...
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
September 29, 2016 01:36 ET
|
MorphoSys AG
Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis
Favorable safety results shown in healthy volunteers receiving single...
Lanthio Pharma Expands Management Team
September 19, 2016 01:40 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Sept. 19, 2016 (GLOBE NEWSWIRE) -- The Dutch biopharmaceutical company Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG (FSE: MOR; Prime Standard Segment,...
MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board
September 12, 2016 01:38 ET
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Sept. 12, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the appointment of four leading experts to its...